USA letzter Kurs gestern $1.50
- Info von silicon-investor:
echniclone Corp. is a biopharmaceutical company
engaged in the research, development and
commercialization of targeted cancer therapeutics,
utilizing proprietary collateral tumor targeting
technologies. For the 3 months ended 7/31/99,
revenues fell 18% to $63K. Net loss applic. to Common
fell 22% to $3M. Revenues reflect decreased interest
and other income. Lower loss reflect a decrease in
severance expenses and lower consulting fees.
- News von silicon-investor
SuperGen Licenses Angiogenesis Drug-Targeting Technology from Techniclone
www.siliconinvestor.com/research/story.gsp?s=TCLN&id=361951
